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Abstract
Background: Chronic myeloid leukemia (CML) comprises ~3 % of pediatric leukemia. Although therapy with
tyrosine kinase inhibitors (TKIs) is highly effective for CML, multiple factors have been identified as predictive of
treatment failure. Chromosomal abnormalities involving the MECOM locus at 3q26 portend therapy resistant disease
in adults, yet have never been described in pediatric patients and have not been associated with T lymphoblastic
progression.
Case presentation: We present a case of an 11-year-old boy with CML possessing the unique combination of
T lymphoblastic transformation and a subclone harboring inv(3)(q21q26.2) at diagnosis. This is the first reported
case of pediatric CML with inv(3)(q21q26.2) and the first case of T lymphoblastic progression associated with this
karyotype. The patient was treated with single agent TKI therapy with robust initial response. Marrow histology at
one month showed restoration of trilineage hematopoiesis and BCR-ABL RT-PCR at three months showed a 1.4 log
reduction in transcript levels.
Conclusions: The karyotypic abnormality of inv(3)(q21q26.2) in CML is not restricted to adult patients. Moreover,
while chromosome 3 abnormalities are markers of TKI resistance in adults, our patient showed a robust early
response to single agent TKI therapy. This finding suggests pediatric CML with inv(3)(q21q26.2) may have distinct
features and more favorable treatment responses than those described in adults.
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Background
Chronic myeloid leukemia (CML) is a myeloproliferative
neoplasm characterized morphologically by over-
production of maturing granulocytes and genetically by
the BCR-ABL1 fusion oncogene. CML constitutes 15–
20 % of adult leukemia [1] yet is uncommon in children,
comprising only 2–3 % of all pediatric leukemia [2]. The
natural history of CML is either biphasic or triphasic,
with progression from an indolent chronic phase (CP) to
a terminal blast phase (BP), occasionally through an
intermediate or accelerated phase (AP). Advanced
disease is infrequent at diagnosis, with only 15 % of
adult and 5 % of pediatric patients initially presenting
with AP or BP [2, 3]. Morphologically, BP resembles
acute leukemia and is not restricted to the myeloid
lineage, indicating that very early hematopoietic progeni-
tors harbor the BCR-ABL1 translocation. Between 50–
65 % of CML-BP shows myeloid differentiation, while
lymphoid and undifferentiated phenotypes comprise 20–
25 % and 15–25 %, respectively [4, 5]. The majority of
lymphoid BP in CML is B lymphoblastic, while T lympho-
blastic transformation is rare.
The hallmark karyotypic abnormality of CML is
t(9;22)(q34;q11), yet complex translocations, such as
t(6;9;22), are seen in 5–10 % of cases. The resulting BCR-
ABL1 fusion protein is sensitive to imatinib and related
tyrosine kinase inhibitors (TKIs). Use of these agents has
vastly improved prognosis; however, a subset of patients
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progress to AP or BP despite adequate treatment, and
prognosis for CML-BP remains poor [6].
Progression from CP to AP and BP is associated with
acquisition of additional chromosomal abnormalities
(ACAs). ACAs of trisomy 8, isochromosome 17q, and
Philadelphia chromosome amplification, often referred
to as “major-route” changes, serve as genetic markers of
high-risk disease and are, therefore, sufficient for classi-
fying CML-AP [5, 7]. Less frequent “minor-route” ACAs
are more varied and have poorly described treatment
implications. One notable exception is abnormalities of
3q26.2 resulting in overexpression of the MECOM locus
[8, 9]. Increased expression of MECOM, an oncogenic
transcription factor involved in hematopoietic stem cell
renewal and differentiation, is associated with resistance
to TKIs and progression to myeloid CML-BP [10–13].
Recently, rearrangements involving the 3q26.2 locus
have been shown to be an independent predictor of
inferior outcomes in adults with CML [14]. As such,
3q26.2 alterations, found either directly by genetic assays
or indirectly by determination of MECOM expression
levels, may be markers for subclassification of patients
with CML. Of note, 3q26.2 locus abnormalities have not
been reported in pediatric CML and thus are of uncer-
tain significance in this population.
We report a case of pediatric CML with the unique
combination of T lymphoblastic progression and a sub-
clone harboring inv(3)(q21q26.2) at diagnosis. This is
the first reported case of CML in which inv(3)(q21q26.2)
occurs simultaneously with T lymphoblastic progression,
as well as the first reported instance of inv(3)(q21q26.2)
in pediatric CML. Notably, immunohistochemical stain-
ing (IHC) of the bone marrow using a novel antibody
against MECOM demonstrated the T lymphoblastic
population to be independent of the subpopulation with
inv(3)(q21q26.2). Despite these adverse features, the
patient initially responded well to TKI monotherapy. We
discuss the diagnostic, prognostic, and therapeutic impli-
cations for this patient and for patients with CML with
inv(3)(q21q26.2) in general.
Case presentation
The patient is an 11-year-old male with attention deficit
hyperactivity disorder (ADHD) who presented with an
unintentional 20 lb. weight loss that was initially attributed
to ADHD medication. Exam was notable for cervical
lymphadenopathy. Laboratory workup showed leukocytosis
with left-shifted granulocytes (WBC 210,000 cells/μL; 65 %
neutrophils, 6 % bands, 5 % lymphocytes, 3 % monocytes,
2 % eosinophils, 3 % metamyelocytes, 13 % myelocytes,
2 % promyelocytes, 1 % blasts), normocytic anemia (Hgb
10.8 g/dL, MCV 92 fL), elevated LDH (1,858 U/L), and
elevated uric acid (7.0 mg/dL). Abdominal CT scan showed
splenomegaly.
A bone marrow study revealed hypercellular marrow
(>95 %) with increased myeloid cells at all stages of
maturation, increased eosinophils, scattered basophils,
few erythroid progenitors, so-called dwarf megakaryo-
cytes, and sea-blue histiocytes (Fig. 1a–d). Blasts were
<5 % morphologically. Flow cytometry identified a popu-
lation of atypical CD3+ MPO- TDT+ T lymphoblasts
(9 % of total events). IHC of the bone marrow core
biopsy confirmed these latter findings, showing individ-
ual and clusters of CD3+ TDT+ T lymphoblasts
comprising ~10 % of overall cellularity and 20–30 % of
cells in restricted areas (Fig. 1d–g).
RT-PCR from peripheral blood was positive for the
BCR-ABL1 p210 transcript. Cytogenetic analysis of the
bone marrow showed 46,XY,t(6;9;22)(p22;q34;q11.2)[9]/
46,sl,inv(3)(q21q26.2)[11], confirming the presence of a
variant three-way translocation generating the BCR-
ABL1 fusion. The presence of a subclone (11 of 20 cells
analyzed) with inv(3)(q21q26.2) suggested disease pro-
gression. Following identification of this inversion and
validation of a novel MECOM antibody, combined IHC
for MECOM and CD3 was performed on the bone marrow
core biopsy. Interestingly, the CD3+ population and the
MECOM-overexpressing population were non-overlapping
(Fig. 1h), indicating the T lymphoblastic transformation
was independent of the acquisition of inv(3)(q21q26.2).
Based on these findings, a diagnosis of CML with T
lymphoblastic transformation was rendered. The patient
was started on hydroxyurea and allopurinol, followed by
single-agent treatment with imatinib (500 mg daily).
Repeat bone marrow studies on day 25 of treatment
showed restoration of trilineage hematopoiesis and
normal cellular morphology, with abnormal T lympho-
blasts comprising 1 % of total cellularity by flow cytome-
try. Subsequent to this study, he was transitioned from
imatinib to dasatinib (100 mg daily) due to the develop-
ment of oral ulcers, and continued to improve clinically
on TKI alone. A third bone marrow biopsy and aspirate
at day 54 showed 0.02 % T lymphoblasts. Peripheral
blood quantitative RT-PCR analysis at three months
showed a 1.4 log reduction of BCR-ABL1 transcripts
(4.3 % IS units) (Table 1). Despite this response to TKI
monotherapy, a matched unrelated stem cell donor was
identified and transplantation is scheduled given the high-
risk features of his disease.
Conclusions
We describe a case of pediatric CML with variant trans-
location t(6;9;22)(p22;q34q11.2) and two identifiable sub-
clonal populations at presentation, one of which harbors
inv(3)(q21q26.2) while the other is comprised of abnormal
T lymphoblasts. CML is rare in the pediatric population,
and only 5 % of patients have evidence of advanced
disease at presentation [2]. Given the T lymphoblasts
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identified at diagnosis, a primary lymphoblastic process
was considered; however, many of the features of this case
favor a diagnosis of CML with T lymphoblastic pro-
gression, including: splenomegaly; peripheral blood with
left-shifted granulocytosis and a marked increase in
myelocytes; myeloid hyperplasia, dwarf megakaryocytes,
and sea-blue histiocytes in the marrow; and t(6;9;22)
producing the p210 BCR-ABL1 transcript. Although the
possibility of two independent processes (CML and T
lymphoblastic lymphoma) was not formally disproven, a
single disease entity (CML with progression) is more
likely.
T lymphoblastic progression of CML is particularly
rare [5]. Our patient did not meet formal WHO mor-
phologic or genetic criteria for AP or BP [7]; however,
recent studies in adult patients suggested flow cytomet-
ric detection of abnormal lymphoid populations at
diagnosis to be highly predictive of rapid progression
Fig. 1 Morphologic and immunohistochemical evaluation of diagnostic bone marrow aspirate and core biopsy. Diagnostic bone marrow aspirate
(a and b, Wright-Giemsa, 600x) and biopsy (c, h & e, 200x) showing myeloid elements at all stages of maturation. The aspirate shows that blasts
are not markedly increased and cells with cytology consistent with lymphoblasts are not readily apparent. Eosinophils (green arrows), basophils
(arrowhead) and dwarf megakaryocytes (black arrows) are identified. Immunohistochemical staining of the bone marrow biopsy (100x) shows
an expansion of CD34(subset) + TDT+ blasts (d and e, respectively) that form clusters. An expansion of CD3+ T-cells (f) without an expansion of
CD19+ B-cells (g) is seen. In panel h, double staining of the biopsy (400x) shows that MECOM expressing cells (brown nuclear stain) are distinct
from CD3+ T-cells (red membranous stain)
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despite adequate treatment with TKIs [15]. Surprisingly,
an expansion of lymphoblasts was not identified in the
marrow aspirate smears, which is likely due to the non-
uniform distribution of the lymphoblasts in the bone mar-
row. This finding indicates that extensive immunopheno-
typic and genetic evaluation of the marrow should be
undertaken to rule out AP or BP even if the bone marrow
aspirate smear demonstrate CP only.
Given the coincident T lymphoblastic transformation
and inv(3)(q21q26.2), we performed IHC for both MECOM
and CD3 and showed that the T lymphoblasts likely did
not harbor the chromosome 3 inversion. The finding that
these populations were independent was not altogether
unexpected, as most cases of CML with inv(3)(q21q26.2)
are associated with thrombocytosis, thrombosis, and
dysmegakaryopoiesis rather than T lymphoblastic trans-
formation [16]. Indeed, the most recent and comprehen-
sive analysis of CML with chromosome 3 alterations [14]
contained no cases with T lymphoblastic transformation.
MECOM is a zinc finger transcription factor whose
overexpression promotes leukemogenesis via several
mechanisms, including apoptotic resistance through direct
transcriptional modulation [17] and epigenetic changes
via promoter DNA methylation [18]. MECOM has been
extensively studied in acute myeloid leukemia and myelo-
dysplastic syndromes, in which increased expression is
associated with poor prognosis [7, 19–21]. High levels of
MECOM have also been detected in CML-BP [10] as well
as a subset of patients with CML-CP with resistance to
TKIs [14, 22]. Currently, the customary method for de-
tecting MECOM overexpression is restricted to RT-PCR
from tumor mRNA and is not standard practice in the
clinical setting. Our detection of MECOM protein expres-
sion in the bone marrow core biopsy suggests that IHC
may be a useful clinical method of evaluating MECOM
expression and may potentially serve as a marker for high-
risk disease.
ACAs are common at diagnosis in CML in any phase
of disease, and “major-route” cytogenetic changes such
as trisomy 8, isochromosome 17q, and amplification of
the Philadelphia chromosome suggest both clonal evolu-
tion and adverse prognosis. While MECOM abnormalities
are not formal “major-route” alterations, recent analysis
identified abnormalities involving 3q26.2 in roughly 3 % of
adult patients with CML and found them to be at par-
ticular risk for disease progression with near uniform
unresponsiveness to TKIs [14]. In this study, none of
the patients with inv(3)(q21q26.2) or t(3;3;)(q21;q26.2)
showed sustained major molecular response (MMR)
or complete cytogenetic response (CCyR). This finding
was consistent with earlier studies in animal models
demonstrating TKI resistance in Evi1-overexpressing cells
in both CML-CP and CML-BP cells [12]. Additionally,
studies in adult CML have found MECOM rearrange-
ments to be associated with evolution of TKI resistance
and progression to myeloid blast crisis despite adequate
therapy [11, 13]. Given these associations, genetic detec-
tions of 3q26.2 abnormalities or immunohistochemical
detection of MECOM overexpression in CML are poten-
tially valuable markers for high-risk disease.
Based on the adult literature of CML with 3q26.2
rearrangements, we were unsure if our patient would
respond to TKI monotherapy; however, after three
months of treatment, BCR-ABL1 transcript level had
fallen to 4.3 % (IS). Multiple studies of adult (and a few
adolescent) patients with CML receiving TKI therapy
have found early molecular response (EMR), defined as
BCR-ABL1 transcript levels ≤10 % (IS) at 3 months, to
Table 1 Clinical course
Day of TKI treatment Clinical event qPCR BCR/ABL, Blood (IS units) qPCR BCR/ABL, Marrow (IS units) T lymphoblasts, Marrow
−1 CML diagnosis confirmed 44 % 9 %
1 Started imatinib 500 mg daily
22 58 %




49 Started dasatinib 100 mg daily 56 %




Timeline of clinical events, BCR-ABL1 transcript levels detected by qPCR in the blood and bone marrow, and percentage of T lymphoblasts in the bone marrow as
measured by flow cytometry. Timeline is reported relative to day 1 of treatment with imatinib. TKI tyrosine kinase inhibitor, qPCR quantitative polymerase chain
reaction, IS international standard units
Lewen et al. Biomarker Research  (2016) 4:14 Page 4 of 6
be associated with significantly higher rates of overall
survival, event- and progression-free survival, CCyR and
MMR [23–25]: in fact, BCR-ABL1 transcript level >10 %
(IS) at three months was found to be the strongest
predictor of poor clinical outcome [25]. Of note, the asso-
ciation between EMR and improved outcomes held true
for patients who required transition to second-generation
TKIs within the first three months due to imatinib failure
or intolerance [24]. Our patient’s robust response to TKI
monotherapy at three months suggests that clinical and
biologic features of CML with inv(3)(q21q26.2) may be
distinct in adult and pediatric patients.
Since the introduction of TKIs, hematopoietic stem cell
transplant (HSCT) in CML has been largely regarded as
salvage therapy for refractory disease. However, a recent
large-scale prospective randomized comparison of TKIs
and early HSCT found HSCT improved both long-term
survival and sustained molecular remission in patients
with high-risk disease and low transplant risk [26]. Given
these results, combined with the lack of data in pediatric
CML with inv(3)(q21q26.2), the high risk of TKI
resistance in adult patients with this genetic abnormality,
and the concomitant T lymphoblastic progression, we
considered allogeneic stem cell transplant to be the best
treatment option.
Abbreviations
ACA, additional chromosomal abnormality; CCyR, complete cytogenetic
response; CML, chronic myeloid leukemia; CML-AP, accelerated phase CML;
CML-BP, blast phase CML; CML-CP, chronic phase CML; EMR, early molecular
response; EVI-1, ecotropic virus integration site 1; HSCT, hematopoietic stem
cell transplant; IHC, immunohistochemistry; IS, international standard units;
MECOM, MDS1 and EVI1 complex locus; MMR, major molecular response;





Availability of data and materials
N/A.
Authors’ contributions
ML reviewed all case material and wrote the manuscript. RG, EC and RA are
the doctors in charge of the present case, reviewed guidelines and studies
regarding treatment of CML, and assisted with manuscript preparation. GW
is the hematopathologist in charge of the initial diagnostic material and
wrote the manuscript. MQ, VP, MP, AB and DF are consulting pathologists
and assisted in manuscript preparation. EH is a consulting hematologist/
oncologist and assisted in manuscript preparation. All authors have read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient’s parent for
publication of this case report and any accompanying images. A copy of the
written consent is available for review by the Editor-in-Chief of this journal.
Ethics approval and consent to participate
N/A.
Author details
1Department of Medicine, Boston Children’s Hospital, Boston, Massachusetts,
USA. 2Nemours Center for Cancer and Blood Disorders, Nemours/Alfred I.
duPont Hospital for Children, Wilmington, Delaware, USA. 3Department of
Pathology and Laboratory Medicine, Nemours/Alfred I. duPont Hospital for
Children, Wilmington, Delaware, USA. 4Department of Pathology and
Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia,
Pennsylvania, USA. 5Department of Pathology and Laboratory Medicine,
Perelman School of Medicine at the University of Pennsylvania, Philadelphia,
Pennsylvania, USA. 6Department of Medicine, Division of Oncology, Perelman
School of Medicine at the University of Pennsylvania, Philadelphia,
Pennsylvania, USA. 7Division of Oncology, Children’s Hospital of Philadelphia,
Philadelphia, Pennsylvania, USA.
Received: 18 April 2016 Accepted: 7 July 2016
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin.
2015;65:5–29.
2. Millot F, Traore P, Guilhot J, Nelken B, Leblanc T, Leverger G, et al.
Clinical and biological features at diagnosis in 40 children with chronic
myeloid leukemia. Pediatrics. 2005;116:140–3.
3. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM.
The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164–72.
4. Derderian PM, Kantarjian HM, Talpaz M, O'Brien S, Cork A, Estey E, et al.
Chronic myelogenous leukemia in the lymphoid blastic phase:
characteristics, treatment response, and prognosis. Am J Med. 1993;94:69–74.
5. Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, et al.
Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.
Am J Med. 1987;83:445–54.
6. Helhmann R. How I, treat CML blast crisis. Blood. 2012;120:737–47.
7. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO
classification of tumours of haematopoietic and lymphoid tissue. 4th ed.
Lyon: International Agency for Research on Cancer; 2008.
8. Groschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BA,
Erpelinck C, et al. A single oncogenic enhancer rearrangement causes
concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014;157:369–81.
9. Yamazaki H, Suzuki M, Otsuki A, Shimizu R, Bresnick EH, Engel JD,
Yamamoto M. A remote GATA2 hematopoietic enhancer drives
leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.
Cancer Cell. 2014;25:415–27.
10. Ogawa S, Kurokawa M, Tanaka T, Tanaka K, Hangaishi A, Mitani K, et al.
Increased Evi-1 expression is frequently observed in blastic crisis of chronic
myelocytic leukemia. Leukemia. 1996;10:788–94.
11. Paquette RL, Nicoll J, Chalukya M, Elashoff D, Shah NP, Sawyers C, et al.
Frequent EVI1 translocations in myeloid blast crisis CML that evolves
through tyrosine kinase inhibitors. Cancer Genet. 2011;204:392–7.
12. Sato T, Goyama S, Kataoka K, Nasu R, Tsuruta-Kishino T, Kagoya Y, et al.
Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor
resistance in chronic myeloid leukemia. Oncogene. 2014;33:5028–38.
13. Theil KS, Cotta CV. The prognostic significance of an inv(3)(q21q26.2) in
addition to a t(9;22)(q34;q11.2) in patients treated with tyrosine kinase
inhibitors. Cancer Genet. 2014;207:171–6.
14. Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HM, et al. Clinical and
prognostic significance of 3q26.2 and other chromosome 3 abnormalities
in CML in the era of tyrosine kinase inhibitors. Blood. 2015;126:1699–706.
15. El Rassi F, Bergsagel JD, Arellano M, Gaddh M, Jillella A, Kota V, et al.
Predicting early blast transformation in chronic-phase chronic
myeloid leukemia: is immunophenotyping the missing link? Cancer.
2015;121:872–5.
16. Bernstein R, Bagg A, Pinto M, Lewis D, Mendelow B. Chromosome 3q21
abnormalities associated with hyperactive thrombopoiesis in acute blastic
transformation of chronic myeloid leukemia. Blood. 1986;68:652–7.
17. Konantz M, Andre MC, Ebinger M, Grauer M, Wang H, Grzywna S, et al.
EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human
acute lymphoblastic leukemia. Leukemia. 2013;27:56–65.
Lewen et al. Biomarker Research  (2016) 4:14 Page 5 of 6
18. Lugthart S, Figueroa ME, Bindels E, Skrabanek L, Valk PJ, Li Y, et al.
Aberrant DNA hypermethylation signature in acute myeloid leukemia
directed by EVI1. Blood. 2011;117:234–41.
19. Barjesteh van Wallwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL,
Valk PJ, van der Poel-van de Luytgaarde S, Hack R, et al. High EVI1
expression predicts poor survival in acute myeloid leukemia: a study of 319
de novo AML patients. Blood. 2003;101:837–45.
20. Lugthart S, Groschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL,
et al. Clinical, molecular, and prognostic significance of WHO type
inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in
acute myeloid leukemia. J Clin Oncol. 2010;28:3890–8.
21. Thol F, Yun H, Sonntag AK, Damm F, Weissinger EM, Krauter J, et al.
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE)
expression in patients with myelodysplastic syndromes. Ann Hematol.
2012;91:1221–33.
22. Daghistani M, Marin D, Khorashad JS, Wang L, May PC, Paliompeis C, et al.
EVI-1 oncogene expression predicts survival in chronic-phase CML patients
resistant to imatinib treated with second-generation tyrosine kinase
inhibitors. Blood. 2010;116:6014–7.
23. Yeung DT, Mauro MJ. Prognostic significance of early molecular response in
chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Hematology Am Soc Hematol Educ Program. 2014;2014:240–3.
24. Branford S, Kim DW, Soverini S, Hague A, Shou Y, Woodman RC, et al.
Initial molecular response at 3 months may predict both response and
event-free survival at 24 months in imatinib-resistant or -intolerant patients
with Philadelphia chromosome-positive chronic myeloid leukemia in
chronic phase treated with nilotinib. J Clin Oncol. 2012;30:4323–9.
25. Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, et al.
Assessment of BCR-ABL1 transcript levels at 3 months is the only
requirement for predicting outcome for patients with chronic myeloid
leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30:232–8.
26. Gratwohl A, Pfirrmann M, Zander A, Kroger N, Beelen D, Novotny J, et al.
Long-term outcome of patients with newly diagnosed chronic myeloid
leukemia: a randomized comparison of stem cell transplantation with drug
treatment. Leukemia. 2016;30:562–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lewen et al. Biomarker Research  (2016) 4:14 Page 6 of 6
